Ελληνικά
English
It wasn't just a building's opening. It was the moment a vision became infrastructure, and that infrastructure started turning into reality.
The park is the first integrated biotechnology park in Southeast Europe. ELPEN invested €72 million of its own capital, with another €8 million coming from investment incentives and support from the Greek State. Behind those numbers isn't just an investment, it's a commitment.
Greece has always had great scientists. What it didn't have was the space to turn that science into something more tangible: companies, funding, know-how, therapies. That's exactly the gap Athens LifeTech Park set out to fill, bringing researchers, investors, entrepreneurs and industry together, so that good science doesn't just stay on paper.
Eleni Pentafragka, CEO of ALTP and Chief Strategy Officer of ELPEN, put it plainly: Greece has the talent and a strong pharmaceutical tradition. What it needed was a stronger ecosystem around it.
Kleanthis Gabriel Xanthopoulos, the man who stood as a founding figure behind the park, put it this way: "Greece always had exceptional science. What it lacked was the ecosystem to turn that science into companies, funding, entrepreneurial experience, specialized infrastructure. That ground is now taking shape, and the park is the first ecosystem to create the infrastructure that supports collaboration and promotes innovation."
And the Prime Minister himself, during his visit, spoke of something bigger than a building: "What we see here today at Athens LifeTech Park is essentially a glimpse of the future and a bridge between Greece and the Greek diaspora."
Today, that ambition finally has a home. Labs where ideas take shape. A place for founders to build their companies. A stage where researchers, entrepreneurs, industry and investors sit at the same table, as equals.
A building made not just to house biotech, but to grow it.
Based in Greece. Looking out at the world. And this is only the beginning.
